INVO Bioscience Inc (OTCQB: IVOB), a medical device company focused on treating infertility with its FDA-cleared INVOcell product, announced on Thursday that it has named Inger Britt Carlsson, PhD as its new vice president of Medical Affairs.
Dr Carlsson will be developing and managing the company's educational symposiums, generating scientific abstracts/publications on the INVOcell technology, and building relationships with key opinion leaders around the world.
Dr Carlsson has more than 30 years' experience in the fertility industry. She was most recently global director of Medical Affairs for CooperSurgical Fertility and Genomics. Prior to CooperSurgical, she was associate director-Medical Affairs for EMD Serono from 2014 to 2015. She has also served as Medical Science Liaison-Medical Affairs for Sanofi Aventis and Medical Science Liaison-Women's Health for Merck. Originally, she started her career at the Centre for Reproduction of Endangered Species at the San Diego Zoo and the Audubon Institute.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial